EUVIMEDEUVIMED entdecken
Crossref

TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast‐Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent

Naseema Gangat iD, Momna Warraich, Sudhesh Kumar, Mahnoor Fatima, Kristen McCullough, Kebede H Begna, Aref Al-Kali, Mrinal M Patnaik, William J Hogan, Abhishek Mangaonkar iD, Antoine N Saliba iD, Mehrdad Hefazi Torghabeh und 8 weitere

American Journal of Hematology · 2026

DOI: 10.1002/ajh.70248 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Naseema Gangat und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic, Mutation. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloproliferative DisordersSulfonamidesBridged Bicyclo Compounds, HeterocyclicMutationBlast CrisisTumor Suppressor Protein p53Antineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleAgedAged, 80 and over

Stichwörter der Autor:innen

JAK2hypomethylatingmyelofibrosispolycythemiathrombocythemia

Substanzen

SulfonamidesBridged Bicyclo Compounds, HeterocyclicvenetoclaxTumor Suppressor Protein p53TP53 protein, human

Autor:innen und Institutionen

  • Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Hematology, Mayo Clinic, Jacksonville, Florida, USA.
  • Division of Hematology, Mayo Clinic, Scottsdale, Arizona, USA.

ORCID-Profile: Naseema Gangat, Abhishek Mangaonkar, Antoine N Saliba, James M Foran, Talha Badar, Ayalew Tefferi

Zitieren

APA

Gangat, N., Warraich, M., Kumar, S., Fatima, M., McCullough, K., Begna, K. H., Al-Kali, A., Patnaik, M. M., Hogan, W. J., Mangaonkar, A., Saliba, A. N., Torghabeh, M. H., Alkhateeb, H., Shah, M. V., Foran, J. M., Badar, T., Palmer, J. M., Yi, C. A., Pardanani, A., & Tefferi, A. (2026). TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast‐Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent. American Journal of Hematology. https://doi.org/10.1002/ajh.70248

Vancouver

Gangat N, Warraich M, Kumar S, Fatima M, McCullough K, Begna KH, et al. TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast‐Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent. American Journal of Hematology. 2026. doi:10.1002/ajh.70248

BibTeX
@article{Gangat2026,
  author = {Gangat, Naseema and Warraich, Momna and Kumar, Sudhesh and Fatima, Mahnoor and McCullough, Kristen and Begna, Kebede H and Al-Kali, Aref and Patnaik, Mrinal M and Hogan, William J and Mangaonkar, Abhishek and Saliba, Antoine N and Torghabeh, Mehrdad Hefazi and Alkhateeb, Hassan and Shah, Mithun V and Foran, James M and Badar, Talha and Palmer, Jeanne M and Yi, Cecilia Arana and Pardanani, Animesh and Tefferi, Ayalew},
  title = {TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast‐Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent},
  journal = {American Journal of Hematology},
  year = {2026},
  doi = {10.1002/ajh.70248}
}
Kostenlos starten →